Letters
Bevacizumab for retinal disorders
Savings from switching to bevacizumab for retinal disorders are underestimated
BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g7522 (Published 10 December 2014) Cite this as: BMJ 2014;349:g7522
- Frank Ahfat, consultant ophthalmic surgeon1
- 1Maidstone and Tunbridge Wells NHS Trust, Maidstone ME16 9QQ, UK
- ahfat99{at}hotmail.com
Lotery and MacEwen report that a switch from ranibizumab to bevacizumab for macular degeneration and other retinal disorders could save the NHS £102m (€129m; $160m) annually.1 In 2012, the IVAN study group suggested annual savings of £84m from such a switch.2 This second …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.